BI Asset Management Fondsmaeglerselskab A S Has $1.69 Million Position in Waters Corporation $WAT

BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Waters Corporation (NYSE:WAT) by 82.3% in the first quarter, HoldingsChannel.com reports. The firm owned 5,670 shares of the medical instruments supplier’s stock after buying an additional 2,559 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Waters were worth $1,689,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in WAT. Zions Bancorporation National Association UT raised its position in Waters by 121.2% in the 4th quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 40 shares during the last quarter. SHP Wealth Management purchased a new position in Waters during the 4th quarter worth $32,000. DV Equities LLC bought a new stake in shares of Waters in the 4th quarter worth $32,000. eCIO Inc. bought a new stake in shares of Waters in the 4th quarter worth $49,000. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of Waters by 39.6% in the fourth quarter. Itau Unibanco Holding S.A. now owns 155 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 44 shares during the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters Stock Up 3.2%

WAT stock opened at $368.70 on Thursday. The stock has a fifty day moving average of $345.08 and a 200-day moving average of $347.45. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15. The company has a market capitalization of $36.20 billion, a price-to-earnings ratio of 46.85, a PEG ratio of 2.16 and a beta of 1.21. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79.

Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. Waters had a return on equity of 15.60% and a net margin of 11.91%.The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the previous year, the business posted $2.25 EPS. The firm’s quarterly revenue was up 91.4% compared to the same quarter last year. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, equities research analysts predict that Waters Corporation will post 14.51 earnings per share for the current year.

Wall Street Analyst Weigh In

WAT has been the topic of several recent analyst reports. Evercore raised shares of Waters from an “in-line” rating to an “outperform” rating and set a $350.00 target price on the stock in a research report on Monday, April 6th. Barclays upped their target price on Waters from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Robert W. Baird set a $387.00 price objective on Waters in a research report on Wednesday, May 6th. UBS Group lifted their price objective on shares of Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Finally, Piper Sandler started coverage on shares of Waters in a research note on Thursday, June 11th. They issued a “neutral” rating and a $400.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Waters has an average rating of “Moderate Buy” and a consensus target price of $394.56.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.